U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C6H5O7.3Mn
Molecular Weight 543.0135
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MANGANESE CITRATE ANHYDROUS

SMILES

[Mn++].[Mn++].[Mn++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=OAVRWNUUOUXDFH-UHFFFAOYSA-H
InChI=1S/2C6H8O7.3Mn/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6

HIDE SMILES / InChI
Molecular Formula C6H5O7
Molecular Weight 189.0997
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Mn
Molecular Weight 54.938
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260883.htm

Manganese citrate is generally recognized as safe direct food additive. Manganese citrate complex has being used in the determination of liver enzyme activities in the aging process and following treatment with aminoethylisothiuronium bromide hydrobromide (AET).

CNS Activity

Originator

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Activator
1430
Activator
1430
Activator
1430
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
Unknown

Approved Use

Manganese is used for prevention and treatment of manganese deficiency, a condition in which the body doesn’t have enough manganese.
Primary
Approved
8429
Unknown

Approved Use

Manganese is used for weak bones (osteoporosis).
Palliative
Approved
8429
Unknown

Approved Use

Early research suggests that taking manganese along with calcium helps improve symptoms of PMS, including pain, crying, loneliness, anxiety, restlessness, irritability, mood swings, depression, and tension.
Curative
Approved
8429
MANGANESE SULFATE

Approved Use

Manganese Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Primary
Approved
8429
MANGANESE SULFATE

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Manganese citrate improves base-calling accuracy in DNA sequencing reactions using rhodamine-based fluorescent dye-terminators.
1999 Mar 1
Manganese: brain transport and emerging research needs.
2000 Jun
Manganese citrate chemistry: syntheses, spectroscopic studies, and structural characterizations of novel mononuclear, water-soluble manganese citrate complexes.
2000 Sep 4
Glutamate/aspartate transporter (GLAST), taurine transporter and metallothionein mRNA levels are differentially altered in astrocytes exposed to manganese chloride, manganese phosphate or manganese sulfate.
2002 Sep
Manganese distribution across the blood-brain barrier. I. Evidence for carrier-mediated influx of managanese citrate as well as manganese and manganese transferrin.
2003 Jan
Bi- and poly-metallic cyanide-bridged complexes of the redox-active cyanomanganese nitrosyl unit [Mn(CN)(PR3)(NO)(eta-C5H4Me)].
2004 Feb 21
Persistent alterations in biomarkers of oxidative stress resulting from combined in utero and neonatal manganese inhalation.
2005 May
CsR(R(6)CoI(12))2 (R = Gd, Er) and (CeI)0.26(Ce(6)MnI(9))2: two new structure types featuring R(6)Z clusters.
2006 Nov 27
Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain.
2009 Sep
Chronic exposure to manganese sulfate leads to adverse dose-dependent effects on the neurobehavioral ability of rats.
2016 Nov
Top-Down Strategy to Synthesize Mesoporous Dual Carbon Armored MnO Nanoparticles for Lithium-Ion Battery Anodes.
2017 Apr 12
Patents

Patents

04048185
23
05089050
24
05261953
23
05629274
23
05700944
23
06136455
24
06548713
23
07091342
25
07384965
26
07544707
26
07598266
24
07615520
24
08460631
23
20020169331
23
20050222440
23
20060205615
24
20060205744
23
20090196809
23
20110203659
23
6589693
23
6627256
23
7435361
26
7687047
23
CA2165259A1
23
CA2517370C
23
DE102016209961
23
EP1627663A3
23
JP 2001058829 A
23
US 3585022 A
23
US20150218342
23
US2825631
23
US2916504
23
US2952519
26

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Curator's Comment: In vitro cytotoxicity of manganese oxide (MnO) using live/dead cell assay, lactate dehydrogenase assay, and reactive oxygen species detection with variation of the concentration of nanoparticles (5-500 ug/ml), incubation time (18-96 h), and different human cell lines (lung adenocarcinoma, breast cancer cells, and glioblastoma cells) was studied. The cytotoxic effect was negligible for 18 h incubation even at highest concentration of 500 ug/ml MnO nanoparticle.
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:20:12 UTC 2023
Edited
by admin
on Sat Dec 16 02:20:12 UTC 2023
Record UNII
74NE0422XH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MANGANESE CITRATE ANHYDROUS
Common Name English
TRIMANGANESE DICITRATE
Systematic Name English
MANGANESE CITRATE [INCI]
Common Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, MANGANESE(2+) SALT (2:3)
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID6047496
Created by admin on Sat Dec 16 02:20:12 UTC 2023 , Edited by admin on Sat Dec 16 02:20:12 UTC 2023
PRIMARY
FDA UNII
74NE0422XH
Created by admin on Sat Dec 16 02:20:12 UTC 2023 , Edited by admin on Sat Dec 16 02:20:12 UTC 2023
PRIMARY
PUBCHEM
9937209
Created by admin on Sat Dec 16 02:20:12 UTC 2023 , Edited by admin on Sat Dec 16 02:20:12 UTC 2023
PRIMARY
ECHA (EC/EINECS)
233-027-3
Created by admin on Sat Dec 16 02:20:12 UTC 2023 , Edited by admin on Sat Dec 16 02:20:12 UTC 2023
ALTERNATIVE
CAS
10024-66-5
Created by admin on Sat Dec 16 02:20:12 UTC 2023 , Edited by admin on Sat Dec 16 02:20:12 UTC 2023
NON-SPECIFIC STOICHIOMETRY
SMS_ID
100000076487
Created by admin on Sat Dec 16 02:20:12 UTC 2023 , Edited by admin on Sat Dec 16 02:20:12 UTC 2023
PRIMARY
CAS
10060-26-1
Created by admin on Sat Dec 16 02:20:12 UTC 2023 , Edited by admin on Sat Dec 16 02:20:12 UTC 2023
PRIMARY
ECHA (EC/EINECS)
233-193-7
Created by admin on Sat Dec 16 02:20:12 UTC 2023 , Edited by admin on Sat Dec 16 02:20:12 UTC 2023
PRIMARY
Related Record Type Details
Structure of MANGANESE CITRATE DECAHYDRATE
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of MANGANOUS CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966